JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients.
View / Open Files
Authors
Publication Date
2018-12Journal Title
Leuk Res
ISSN
0145-2126
Publisher
Elsevier BV
Volume
75
Pages
71-72
Language
eng
Type
Article
This Version
AM
Physical Medium
Print-Electronic
Metadata
Show full item recordCitation
Gallipoli, P. (2018). JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients.. Leuk Res, 75 71-72. https://doi.org/10.1016/j.leukres.2018.10.010
Keywords
Antineoplastic Agents, Humans, Janus Kinase 2, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Nitriles, Protein Kinase Inhibitors, Pyrazoles, Pyrimidines
Sponsorship
Medical Research Council (MC_PC_12009)
Wellcome Trust (109967/Z/15/Z)
Identifiers
External DOI: https://doi.org/10.1016/j.leukres.2018.10.010
This record's URL: https://www.repository.cam.ac.uk/handle/1810/286785
Rights
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk